Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Nantes – page 65

951 clinical trials in Nantes, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Nantes at a glance
951
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

951 trials in Nantes

Open in trial search

Study Comparing Asciminib with Other Drug Combinations for Adults with Newly Diagnosed Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Study on the Safety and Effectiveness of Epcoritamab, Venetoclax, and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Genmab A/S

Hidradenitis

Not recruiting

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.

Study Comparing Subcutaneous and Intravenous Isatuximab with Pomalidomide and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Dexamethasone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Retinitis pigmentosa

Not recruiting

Study of HORA-PDE6B's Safety in Retinitis Pigmentosa Patients with PDE6B Gene Mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Atropine Sulfate
  • Sponsor:eyeDNA Therapeutics

Study on Acalabrutinib with Drug Combination for Patients 75 and Older with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Study of BI 764198 for Patients with Focal Segmental Glomerulosclerosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim International GmbH

Mantle cell lymphoma

Not recruiting

Study on Ibrutinib, CD20 Ab and Venetoclax for Patients with Untreated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:LYSARC

Study of Tisagenlecleucel for Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Novartis Pharma AG

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daiichi Sankyo Inc.

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mrna-4157
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study of Venetoclax, Daratumumab, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Nantes

What the registry says about research in the country

01 Oncology and Hematology

Advanced research focusing on multiple myeloma, leukemia, and various lymphomas. Studies are evaluating novel treatment combinations and therapeutic approaches for blood cancers.

  • Multiple Myeloma Treatments
  • Lymphoma Therapies
  • Leukemia Management

Innovative trials exploring combinations of targeted therapies and immunotherapies to improve patient outcomes.

02 Infectious Diseases

Comprehensive studies on preventive measures against viral infections, including trials for vaccines targeting CMV, yellow fever, and mpox.

  • Vaccine Development
  • Viral Prevention
  • Immunization Studies

Focus on developing and evaluating new vaccine formulations and delivery methods.

03 Autoimmune Conditions

Research investigating treatments for inflammatory bowel diseases and multiple sclerosis, including innovative approaches like fecal microbiota transplantation.

  • Crohn's Disease
  • Ulcerative Colitis
  • MS Treatment Strategies

Exploring novel therapeutic options and treatment de-escalation strategies.

04 Critical Care Medicine

Studies addressing postoperative care and management of severe conditions in intensive care settings, including burns and immune suppression.

  • Post-Surgery Care
  • Burn Treatment
  • ICU Interventions

Evaluating new approaches to improve patient comfort and outcomes in critical care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.